Solidarilty Wealth LLC Sells 127 Shares of Johnson & Johnson (NYSE:JNJ)

Solidarilty Wealth LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 4.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,547 shares of the company’s stock after selling 127 shares during the quarter. Solidarilty Wealth LLC’s holdings in Johnson & Johnson were worth $445,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in JNJ. Palisade Capital Management LLC NJ grew its stake in shares of Johnson & Johnson by 0.3% during the first quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock valued at $16,507,000 after purchasing an additional 250 shares during the last quarter. Lmcg Investments LLC bought a new position in Johnson & Johnson in the first quarter valued at approximately $12,462,000. Capital Wealth Planning LLC boosted its stake in Johnson & Johnson by 14.0% in the first quarter. Capital Wealth Planning LLC now owns 916,575 shares of the company’s stock valued at $162,445,000 after acquiring an additional 112,890 shares during the last quarter. Tandem Investment Advisors Inc. boosted its stake in Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after acquiring an additional 15,003 shares during the last quarter. Finally, Tcwp LLC bought a new position in Johnson & Johnson in the first quarter valued at approximately $946,000. 68.59% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 16,410 shares of the firm’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,366,753.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, VP Peter Fasolo sold 22,864 shares of Johnson & Johnson stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Kathryn E. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,366,753.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 118,795 shares of company stock valued at $20,230,174. Corporate insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research note on Thursday. They issued a “neutral” rating on the stock. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. Raymond James cut their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. StockNews.com started coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Finally, Sanford C. Bernstein cut their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $184.25.

Johnson & Johnson Trading Up 0.8 %

Shares of NYSE:JNJ opened at $174.86 on Friday. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The company’s fifty day simple moving average is $167.63 and its 200 day simple moving average is $171.41. The firm has a market cap of $457.17 billion, a price-to-earnings ratio of 24.35, a PEG ratio of 3.42 and a beta of 0.57.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The business had revenue of $23.79 billion for the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period last year, the business posted $2.60 earnings per share. As a group, research analysts forecast that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has approved a share repurchase plan on Wednesday, September 14th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to buy up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.